Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase.

74Citations
Citations of this article
106Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Indoleamine 2,3-dioxygenase (IDO), a metabolic enzyme that catalyzes tryptophan conversion into kynurenines, is a crucial regulator of immunity. Altered IDO activity is often associated with pathology, including neoplasia and autoimmunity. IDO is highly expressed in dendritic cells (DCs) that exploit the enzyme's activity and the production of tryptophan catabolites to regulate immune responses by acting on several cell types, including T lymphocytes, of which they promote a regulatory phenotype. IDO also contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that, once bound by distinct molecular partners, will either promote degradation or initiate signaling activity and self-maintenance of the enzyme. We here discuss how ITIM-dependent molecular events can affect the functional plasticity of IDO by modifying the protein half-life and its enzymic and nonenzymic functions.

Cite

CITATION STYLE

APA

Orabona, C., Pallotta, M. T., & Grohmann, U. (2012). Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase. Molecular Medicine (Cambridge, Mass.). https://doi.org/10.2119/molmed.2012.00029

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free